CRA experts advised counsel and presented before the FTC on transactions involving Novartis’ acquisition of cancer drugs from GlaxoSmithKline, GSK’s joint venture with Novartis on consumer health, and Novartis’s sale of Novartis Animal Health to Eli Lilly & Co. The deals ultimately went forward with certain divestitures.
CRA expands its Antitrust Practice with addition of M&A specialist and litigation expert
“I am pleased to welcome Hitesh back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He specializes in antitrust...